Xconomy: AbbVie News, Articles and Opinions

“abbvie” Archives

Entry	Author	Date	Location
With FDA’s Eye on JAK Drugs, Concert Moves One Ahead For Hair Loss	Ben Fidler	09/03/19	Boston
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More	Alex Lash	08/30/19	National
$5.8B for Nothing: AbbVie Shelves Stemcentrx Drug After Latest Flop	Ben Fidler	08/29/19	Detroit Ann Arbor
Celgene to Sell Blockbuster Drug to Amgen for $13B to Close BMS Deal	Frank Vinluan	08/26/19	New York
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More	Frank Vinluan	08/23/19	National
New BC Biotech Chinook Reels in $65M to Tackle Kidney Disease	Sarah de Crescenzo	08/22/19	National
AbbVie’s Successor to Humira Wins FDA OK for Rheumatoid Arthritis	Sarah de Crescenzo	08/16/19	National
Bio Roundup: Zolgensma Fallout, Duchenne Redux, Ebola Boost & More	Alex Lash	08/16/19	National
Four New Drugs Are Around the Corner. Here’s What You Need to Know.	Ben Fidler	08/15/19	National
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More	Frank Vinluan	08/02/19	National
Bio Roundup: Leiden’s Exit, Depression Data, a New Pricing Bill & More	Ben Fidler	07/26/19	National
Bio Roundup: Opioid Exposé, Gilead’s Gambit, Life Science IPOs & More	Frank Vinluan	07/19/19	National
Bio Roundup: Merger Drama, FDA Trauma, Big IPOs, CRISPR Fights & More	Alex Lash	06/28/19	National
AbbVie to Pay $63B for Allergan to Prepare for Life Without Humira	Ben Fidler	06/25/19	Detroit Ann Arbor
Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More	Frank Vinluan	06/21/19	National
Oncternal Therapeutics Goes Public After Reverse Merger With GTx	Sarah de Crescenzo	06/12/19	San Diego
Bio Roundup: Zolgensma Watch, Brain Cancer Blues, Peloton Payout & More	Alex Lash	05/24/19	National
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More	Frank Vinluan	04/26/19	National
Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More	Frank Vinluan	03/15/19	National
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away	Alex Lash	02/26/19	National
Voyager Therapeutics, AbbVie Add Parkinson’s to Gene Therapy Pact	Frank Vinluan	02/22/19	Boston
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More	Frank Vinluan	02/22/19	National
AbbVie Joins Myeloma Race with $90M Deal for Rights to Teneobio Drug	Frank Vinluan	02/11/19	San Francisco
Alector IPO Banks $176M to Test Alzheimer’s Drugs in Clinical Trials	Frank Vinluan	02/06/19	San Francisco
Halozyme Gets $30M from Argenx in Licensing Deal Worth Up to $530M	Sarah de Crescenzo	02/06/19	San Diego
Alector Files for IPO to Fund Studies of Alzheimer’s, Dementia Drugs	Frank Vinluan	01/07/19	San Francisco
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More	Alex Lash	01/04/19	National
Tizona Lands $105M from AbbVie in Cancer Drug R&D Alliance	Frank Vinluan	01/03/19	San Francisco
Acorda Gets FDA Nod for New Parkinson’s Drug, But Rival Looms	Ben Fidler	12/24/18	New York
Gilead, Scholar Rock Sign $80M Up Front Deal for Fibrosis Drugs	Corie Lok	12/19/18	Boston
Page 1 of 6	next page »

Underwriters and Partners

Xpertise: Watch + Learn

Sponsored · Whitepaper
Protecting Valuable Life Science Assets & Equipment: Monitoring Solutions
Remain compliant and ensure optimal productivity
XiltriX

Xconomy Insight · Webinar
The New Era of Emerging Therapies Webinar Series
Potential cures and treatments for diseases are on the horizon for a growing number of patients, thanks to recent breakthroughs in CRISPR gene-editing technologies and in cell and gene therapy.

Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes